argenx SE (0QW0.IL)
| Previous close | 383.55 |
| Open | 382.00 |
| Bid | 362.40 x N/A |
| Ask | 400.50 x N/A |
| Day's range | 375.50 - 385.30 |
| 52-week range | 224.50 - 405.10 |
| Volume | |
| Avg. volume | 32,356 |
| Market cap | 19.65B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.37 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
argenx Enters Into Agreement To Acquire Priority Review Voucher
Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of a single Biologics License Application (BLA), which reduces the target review period and may lead to an expedited appr
- Globe Newswire
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023 - Submission based on positive results from the Phase 3 bridging study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod compared to intravenous (IV) administration November 22, 2022 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, to
- Globe Newswire
argenx to Present at Upcoming Investor Conferences
November 7, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in several upcoming investor conferences in November: Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day. Fireside chat on Monday, November 14, 2022 at 11:20 a.m. ET in New York, NY.Stifel 2022 Healthcare Conference. Fireside chat
